A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

被引：0

作者：

Autumn J. McRee

Janine M. Davies

Hanna G. Sanoff

Richard M. Goldberg

Stephen Bernard

E. Claire Dees

Kimberly Keller

Anastasia Ivanova

Bert H. O’Neil

机构：

[1] The University of North Carolina at Chapel Hill,Department of Medicine, Division of Hematology/Oncology, School of Medicine

[2] BC Cancer Agency,School of Medicine

[3] The Ohio State University,School of Medicine

[4] Indiana University,Department of Medicine

来源：

Cancer Chemotherapy and Pharmacology | 2014年 / 74卷

关键词：

Everolimus; 5-Fluorouracil; Oxaliplatin; Panitumumab; Metastatic colorectal cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：117 / 123

页数：6

共 50 条

[31] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
Uetake, Hiroyuki
Emi, Yasunori
Yamanaka, Takeharu
Muro, Kei
Oki, Eiji
Takahashi, Takao
Nagasaka, Takeshi
Hatano, Etsuro
Ojima, Hitoshi
Manaka, Dai
Kusumoto, Tetsuya
Katayose, Yu
Fujiwara, Toshiyoshi
Yoshida, Kazuhiro
Unno, Michiaki
Hyodo, Ichinosuke
Tomita, Naohiro
Sugihara, Kenichi
Maehara, Yoshihiko
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[32] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
van Hazel, Guy A.
Heinemann, Volker
Sharma, Navesh K.
Findlay, Michael P. N.
Ricke, Jens
Peeters, Marc
Perez, David
Robinson, Bridget A.
Strickland, Andrew H.
Ferguson, Tom
Rodriguez, Javier
Kroening, Hendrik
Wolf, Ido
Ganju, Vinod
Walpole, Euan
Boucher, Eveline
Tichler, Thomas
Shacham-Shmueli, Einat
Powell, Alex
Eliadis, Paul
Isaacs, Richard
Price, David
Moeslein, Fred
Taieb, Julien
Bower, Geoff
Gebski, Val
Van Buskirk, Mark
Cade, David N.
Thurston, Kenneth
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
[33] A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Shanda, Safi
Noonan, Anne M.
Bekaii-Saab, Tanios S.
O'Neil, Bert H.
Sehdev, Amikar
Shaib, Walid Labib
Helft, Paul R.
Loehrer, Patrick J.
Tong, Yan
Liu, Ziyue
El-Rayes, Bassel F.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[34] PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Schwartzberg, Lee S.
Rivera, Fernando
Karthaus, Meinolf
Fasola, Gianpiero
Canon, Jean-Luc
Hecht, J. Randolph
Yu, Hua
Oliner, Kelly S.
Go, William Y.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2240 - +
[35] EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).
Mise, Yoshihiro
Hasegawa, Kiyoshi
Oba, Masaru
Yamaguchi, Kensei
Uetake, Hiroyuki
Yoshino, Takayuki
Morita, Satoshi
Takahashi, Keiichi
Unno, Michiaki
Shimada, Yasuhiro
Muro, Kei
Yoshida, Kazuhiro
Mori, Masaki
Baba, Hideo
Shimada, Mitsuo
Saiura, Akio
Matsumura, Masaru
Ishigure, Kiyoshi
Sugihara, Kenichi
Kokudo, Norihiro
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[36] Safety and Efficacy of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naive Metastatic Colorectal Cancer (SAPPHIRE)
Nagata, N.
Mishima, H.
Kurosawa, S.
Oba, K.
Sakamoto, J.
ANNALS OF ONCOLOGY, 2016, 27 : 80 - 80
[37] Safety and efficacy of mFOLFOX6+panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in patients with chemotherapy-naive metastatic colorectal cancer (SAPPHIRE)
Nagata, N.
Mishima, H.
Kurosawa, S.
Oba, K.
Sakamoto, J.
ANNALS OF ONCOLOGY, 2015, 26 : 68 - 68
[38] The SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer [SOFT Study Group]
Matsumoto, H.
Yamada, Y.
Takahari, D.
Baba, H.
Yoshida, K.
Komatsu, Y.
Satoh, T.
Muro, K.
Shimada, Y.
Sugihara, K.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S486 - S487
[39] Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).
Nakamura, Masato
Yamada, Yasuhide
Takahari, Daisuke
Matsumoto, Hiroshi
Baba, Hideo
Yoshida, Kazuhiro
Yoshida, Motoki
Iwamoto, Shigeyoshi
Shimada, Ken
Komatsu, Yoshito
Sasaki, Yasutsuna
Satoh, Taroh
Takahashi, Keiichi
Mishima, Hideyuki
Muro, Kei
Watanabe, Masahiko
Sakata, Yuh
Morita, Satoshi
Shimada, Yasuhiro
Sugihara, Kenichi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study.
Takahari, Daisuke
Yamada, Yasuhide
Matsumoto, Hiroshi
Baba, Hideo
Yoshida, Kazuhiro
Nakamura, Masato
Yoshida, Motoki
Iwamoto, Shigeyoshi
Takinishi, Yasutaka
Sakata, Yuh
Morita, Satoshi
Shimada, Yasuhiro
Komatsu, Yoshito
Sasaki, Yasutsuna
Satoh, Taroh
Takahashi, Keiichi
Mishima, Hideyuki
Muro, Kei
Watanabe, Masahiko
Sugihara, Kenichi
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →